FTC Will Push To Block $3.1B CSL-Talecris Merger

Law360 (May 26, 2009, 12:00 AM EDT) -- Federal Trade Commission staff members oppose blood plasma-derived therapeutics company CSL Ltd.'s proposed $3.1 billion acquisition of rival Talecris Biotherapeutics and have asked the agency to block the deal, CSL has announced.

Commissioners told CSL managing director Brian McNamee in a meeting Friday that FTC staff recommended that the agency take action in federal court to stop the merger, the company revealed Monday.

CSL expects a vote and a decision on the merger from the commission by Thursday, it said.

An FTC spokesman would not comment...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.